Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0B7SP
|
|||
| Former ID |
DCL000371
|
|||
| Drug Name |
GSK163090
|
|||
| Synonyms |
844903-58-8; GSK-163090; UNII-7XI927X82B; CHEMBL1631540; 7XI927X82B; 1-(3-(2-(4-(2-Methyl-5-quinolinyl)-1-piperazinyl)ethyl)phenyl)-2-imidazolidinone; 1-(3-{2-[4-(2-Methyl-5-quinolinyl)-1-piperazinyl]ethyl}phenyl)-2-imidazolidinone; 1-[3-[2-[4-(2-methyl-5-quinolinyl)-1-piperazinyl]ethyl]phenyl]-2-imidazolidinone; ANGUXJDGJCHGOG-UHFFFAOYSA-N; GSK 163090; SCHEMBL2881345; DTXSID30233480; EX-A1027; BCP16941; ZINC34451922; BDBM50333015; AKOS030526918; CS-5315; HY-14348
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Anxiety disorder [ICD-11: 6B00-6B0Z] | Discontinued in Phase 2 | [1] | |
| Episode [ICD-11: N.A.] | Discontinued in Phase 2 | [1] | ||
| Major depressive disorder [ICD-11: 6A70.3; ICD-10: F32.2] | Discontinued in Phase 2 | [1] | ||
| Company |
GSK
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C25H29N5O
|
|||
| Canonical SMILES |
CC1=NC2=C(C=C1)C(=CC=C2)N3CCN(CC3)CCC4=CC(=CC=C4)N5CCNC5=O
|
|||
| InChI |
1S/C25H29N5O/c1-19-8-9-22-23(27-19)6-3-7-24(22)29-16-14-28(15-17-29)12-10-20-4-2-5-21(18-20)30-13-11-26-25(30)31/h2-9,18H,10-17H2,1H3,(H,26,31)
|
|||
| InChIKey |
ANGUXJDGJCHGOG-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 844903-58-8
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
9223, 606306, 841998, 5329924, 7979286, 8152146, 10532904, 11111179, 11111180, 11212325, 11335686, 11360925, 11363183, 11364798, 11365745, 11367360, 11368307, 11369922, 11372419, 11372962, 11374514, 11375522, 11376469, 11378089, 11461897, 11466348, 11467468, 11485013, 11486275, 11489015, 11491235, 11492643, 11494103, 14832617, 24263032, 26751625, 29222507, 46506645, 47291093, 47291094, 47365145, 47588956, 47588957, 47662238, 47662239, 47736435, 47885368, 48110419, 48259193, 48259194
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | 5-HT 1A receptor (HTR1A) | Target Info | Antagonist | [2] |
| KEGG Pathway | cAMP signaling pathway | |||
| Neuroactive ligand-receptor interaction | ||||
| Serotonergic synapse | ||||
| Panther Pathway | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | |||
| 5HT1 type receptor mediated signaling pathway | ||||
| Reactome | Serotonin receptors | |||
| G alpha (i) signalling events | ||||
| WikiPathways | Serotonin HTR1 Group and FOS Pathway | |||
| SIDS Susceptibility Pathways | ||||
| Monoamine GPCRs | ||||
| GPCRs, Class A Rhodopsin-like | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800026154) | |||
| REF 2 | Clinical pipeline report, company report or official report of GlaxoSmithKline (2009). | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.